BioSpace News Archive

Financing to Support Modular Presbyopia-Correcting Accommodating Intraocular Lens Technology

Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that it has appointed Douglas E. Feltner, M.D. as its Chief Medical Officer effective May 18th, 2020.

5 of the top 7 CROs join Vault CDMS CRO partner program to speed the deployment of high-quality clinical trials

On 19 May 2020, Orexo AB held an extraordinary general meeting. The extraordinary general meeting passed the following resolutions.

Biodesix, Inc., a leading diagnostic company in lung disease, announced that it has collaborated with Bio-Rad Laboratories, Inc. to launch a blood-based immunoassay-based test that identifies antibodies to SARS-CoV-2, the virus that causes COVID-19.

Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced it has entered into a material transfer agreement (MTA) and exclusive license option with Shionogi & Co., Ltd. to develop a novel HSV-2 vaccine using Genocea’s proprietary HSV-2 antigens from the GEN-003 program, which the company discontinued in 2017. Under the terms of the agreement, Shionogi

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced the company will make four presentations at the upcoming 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II being held June 22-24, 2020.

Biogen Inc. announced new data from its robust multiple sclerosis treatment portfolio.

Experiment supports Brilacidin’s therapeutic potential as a COVID-19 treatment and as a prophylactic agent against COVID-19

Medela LLC, announced the opening of a new manufacturing line in the U.S. for its Vario 18 AC Portable Suction Pumps, that provide crucial suction and fluid removal during respiratory treatment provided by ventilators.